• 1. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 2. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 3. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors
  Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
• 4. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

Introduction to 1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride (CAS No. 63725-58-6)

1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride, with the chemical identifier CAS No. 63725-58-6, is a heterocyclic compound that has garnered significant attention in the field of pharmaceutical research due to its unique structural properties and potential biological activities. This compound belongs to the pyrazolopyridine class, a scaffold that has been extensively explored for its pharmacological relevance. The presence of both pyrazole and pyridine rings in its structure imparts distinct electronic and steric characteristics, making it a versatile candidate for drug discovery and development.

The hydrochloride salt form of this compound enhances its solubility in aqueous solutions, which is a critical factor for formulation development in medicinal chemistry. This solubility profile facilitates its use in various biochemical assays and preclinical studies, where efficient delivery and absorption are paramount. The amine functional group at the 6-position of the pyrazolopyridine core provides a site for further chemical modifications, enabling the synthesis of derivatives with tailored biological properties.

In recent years, there has been a surge in research focused on developing novel therapeutic agents targeting complex diseases such as cancer, inflammation, and neurodegenerative disorders. The pyrazolopyridine scaffold has emerged as a promising class of compounds due to its ability to modulate multiple biological pathways simultaneously. Specifically, 1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride has been investigated for its potential role in inhibiting kinases and other enzymes involved in cellular signaling pathways associated with disease progression.

One of the most compelling aspects of this compound is its reported activity as a kinase inhibitor. Kinases are enzymes that play a crucial role in regulating various cellular processes, including cell growth, differentiation, and apoptosis. Dysregulation of kinase activity is often implicated in the pathogenesis of cancers and inflammatory diseases. Preclinical studies have demonstrated that 1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride can selectively inhibit certain kinases by binding to their active sites, thereby disrupting aberrant signaling cascades. This mechanism of action makes it a valuable candidate for further development into an anti-cancer therapeutic agent.

Furthermore, the amine hydrochloride form of this compound exhibits favorable pharmacokinetic properties, including good oral bioavailability and moderate metabolic stability. These characteristics are essential for ensuring that the drug reaches effective concentrations at the target site and remains active long enough to exert its therapeutic effect. Additionally, the compound’s solubility profile allows for easy formulation into oral dosage forms, such as tablets or capsules, which enhances patient compliance.

The structural flexibility of 1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride also allows for the synthesis of numerous derivatives through medicinal chemistry strategies such as sulfonamide formation, alkylation, or halogenation. These modifications can fine-tune the biological activity of the compound, improving its potency and selectivity while minimizing off-target effects. Such derivatives have been explored in various preclinical models to evaluate their efficacy against different disease states.

Recent advancements in computational chemistry and high-throughput screening (HTS) have accelerated the discovery process for novel drug candidates like 1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride. These technologies enable researchers to rapidly assess the binding affinity and selectivity of compounds against target proteins, thereby identifying promising candidates for further optimization. Computational modeling has also been used to predict the pharmacokinetic properties of this compound, providing insights into its potential behavior in vivo.

In addition to its kinase inhibitory activity, preliminary studies have suggested that 1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride may exhibit anti-inflammatory properties. Chronic inflammation is a hallmark of many diseases, including arthritis and cardiovascular disorders. By modulating inflammatory pathways, this compound could potentially ameliorate symptoms associated with these conditions. Further research is needed to fully elucidate these effects and determine their clinical relevance.

The synthesis of 1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride involves multi-step organic reactions that require precise control over reaction conditions to ensure high yield and purity. Common synthetic routes include condensation reactions between hydrazines and β-ketoesters or β-diketones to form the pyrazole ring followed by coupling with pyridine derivatives via nucleophilic substitution or cyclization reactions. The final step involves conversion to the hydrochloride salt to enhance stability and solubility.

The availability of high-quality reference standards like CAS No. 63725-58-6 is crucial for researchers engaged in pharmaceutical development. These standards serve as benchmarks for purity analysis and allow for accurate characterization of synthetic intermediates and final products. The use of well-characterized compounds ensures consistency across different experiments and facilitates collaboration between research groups.

As interest in targeted therapies continues to grow, compounds like 1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride are expected to play an increasingly important role in drug discovery pipelines. Their unique structural features offer opportunities for developing drugs with improved efficacy and reduced side effects compared to existing treatments. Ongoing research efforts are focused on optimizing synthetic routes, exploring new derivatives, and conducting preclinical studies to validate their therapeutic potential.

In conclusion,1H-Pyrazolo[3,4-b]pyridin-6-amine hydrochloride (CAS No. 63725-58-6) represents a promising candidate for further pharmaceutical development due to its structural versatility and reported biological activities. Its ability to modulate kinase activity suggests potential applications in treating cancers and inflammatory diseases, while its favorable pharmacokinetic properties make it an attractive option for drug formulation。 With continued research efforts aimed at optimizing its design and evaluating its clinical efficacy, this compound holds significant promise as a future therapeutic agent.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)